

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 69640

Title: Value of Teicoplanin Combined with Conventional Vancomycin Therapy for the Treatment of Pulmonary MRSA and MRSE Infections

Reviewer's code: 06135281

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: Australia

Author's Country/Territory: China

Manuscript submission date: 2021-07-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-02 02:37

Reviewer performed review: 2021-08-15 16:28

Review time: 13 Days and 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Pulmonary infections are typically resistant to treatment with cefradine, oxacillin, or methicillin. Teicoplanin is a novel glycopeptide antibacterial preparation for use in place of vancomycin. This novel drug has enhanced antibacterial activity against MRSA and MRSE due to the addition of fatty acid side chains to its chemical structure, which also increases its molecular mass and half-life, relative to vancomycin. In this study, the authors explored the value of teicoplanin combined with conventional (vancomycin only) anti-infective therapy for the treatment of methicillin-resistant MRSA and MRSE pulmonary infections. The study is overall very well designed and the results are very interesting. The reviewer suggests to accept this study after a minor revision. 1. Some minor language polishing should be revised. 2. A short background should be added to the abstract. 3. Tables should revised and edited, some Chinese characters should be replaced.